233 related articles for article (PubMed ID: 8126059)
21. Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 2000 Aug; 156(1):101-7. PubMed ID: 10840165
[TBL] [Abstract][Full Text] [Related]
22. Human chorionic gonadotropin inhibits N-Methyl-N-nitrosourea-induced mammary carcinoma growth in female Lewis rats.
Yuri T; Lai YC; Yoshizawa K; Tsubura A
In Vivo; 2012; 26(3):361-7. PubMed ID: 22523287
[TBL] [Abstract][Full Text] [Related]
23. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Van Ginckel R; Janssens B; Callens M; Goeminne N; Wouters L; De Coster R
Cancer Chemother Pharmacol; 1996; 38(1):21-8. PubMed ID: 8603447
[TBL] [Abstract][Full Text] [Related]
24. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
[TBL] [Abstract][Full Text] [Related]
25. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats.
Trivedi RN; Chauhan SC; Dwivedi A; Kamboj VP; Singh MM
Contraception; 1995 Jun; 51(6):367-79. PubMed ID: 7554978
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue.
Gibson MK; Nemmers LA; Beckman WC; Davis VL; Curtis SW; Korach KS
Endocrinology; 1991 Oct; 129(4):2000-10. PubMed ID: 1915080
[TBL] [Abstract][Full Text] [Related]
27. Effect of mifepristone and antiestrogens on uterine PGF2 alpha and PGE2 concentrations in ovariectomized and pregnant rats.
Li XJ; Yu H; Koide SS
Prostaglandins; 1997 Mar; 53(3):187-97. PubMed ID: 9206800
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
29. Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Houjou T; Wada T; Yasutomi M
Clin Ther; 1993; 15(1):137-47. PubMed ID: 8458043
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
31. Antagonism of development and growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors.
Tsai TL; Katzenellenbogen BS
Cancer Res; 1977 May; 37(5):1537-43. PubMed ID: 404032
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology of tamoxifen in laboratory animals.
Jordan VC; Allen KE; Dix CJ
Cancer Treat Rep; 1980; 64(6-7):745-59. PubMed ID: 6775807
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse.
Martel C; Labrie C; Bélanger A; Gauthier S; Mérand Y; Li X; Provencher L; Candas B; Labrie F
Endocrinology; 1998 May; 139(5):2486-92. PubMed ID: 9564862
[TBL] [Abstract][Full Text] [Related]
34. Involvement of the adrenal glands in the prolactin rise induced in the female rat by an antiprogestin, onapristone.
Nishino Y; Michna H; Hasan SH; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):841-5. PubMed ID: 1562560
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Schieweck K; Bhatnagar AS; Batzl C; Lang M
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):633-6. PubMed ID: 8476774
[TBL] [Abstract][Full Text] [Related]
36. Induction of mammary epithelial cell differentiation and inhibition of dimethylbenz(A)anthracene-induced mammary tumour by co-administration of a pure antiestrogen ICI 182,780 and testosterone enanthate.
Chan TW; Mark G; Huynh H
Int J Oncol; 2001 Aug; 19(2):263-9. PubMed ID: 11445837
[TBL] [Abstract][Full Text] [Related]
37. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
Zhou JL; Brodie A
J Steroid Biochem Mol Biol; 1995 Jan; 52(1):71-6. PubMed ID: 7857875
[TBL] [Abstract][Full Text] [Related]
38. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
39. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription.
Nawaz Z; Stancel GM; Hyder SM
Cancer Res; 1999 Jan; 59(2):372-6. PubMed ID: 9927049
[TBL] [Abstract][Full Text] [Related]
40. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
